These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 21095237)

  • 1. PGE1 and PGE2 modify platelet function through different prostanoid receptors.
    Iyú D; Jüttner M; Glenn JR; White AE; Johnson AJ; Fox SC; Heptinstall S
    Prostaglandins Other Lipid Mediat; 2011 Feb; 94(1-2):9-16. PubMed ID: 21095237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PGE(2) reverses G(s)-mediated inhibition of platelet aggregation by interaction with EP3 receptors, but adds to non-G(s)-mediated inhibition of platelet aggregation by interaction with EP4 receptors.
    Glenn JR; White AE; Iyu D; Heptinstall S
    Platelets; 2012; 23(5):344-51. PubMed ID: 22436052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of prostanoid receptors in mediating the effects of PGE(2) on human platelet function.
    Iyú D; Glenn JR; White AE; Johnson AJ; Fox SC; Heptinstall S
    Platelets; 2010; 21(5):329-42. PubMed ID: 20433310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostaglandin E2 differentially modulates human platelet function through the prostanoid EP2 and EP3 receptors.
    Petrucci G; De Cristofaro R; Rutella S; Ranelletti FO; Pocaterra D; Lancellotti S; Habib A; Patrono C; Rocca B
    J Pharmacol Exp Ther; 2011 Feb; 336(2):391-402. PubMed ID: 21059804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. P2Y₁₂ and EP3 antagonists promote the inhibitory effects of natural modulators of platelet aggregation that act via cAMP.
    Iyú D; Glenn JR; White AE; Fox SC; Dovlatova N; Heptinstall S
    Platelets; 2011; 22(7):504-15. PubMed ID: 21591981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DG-041 inhibits the EP3 prostanoid receptor--a new target for inhibition of platelet function in atherothrombotic disease.
    Heptinstall S; Espinosa DI; Manolopoulos P; Glenn JR; White AE; Johnson A; Dovlatova N; Fox SC; May JA; Hermann D; Magnusson O; Stefansson K; Hartman D; Gurney M
    Platelets; 2008 Dec; 19(8):605-13. PubMed ID: 19012178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of PGE(2) in human atherosclerotic plaque on platelet EP(3) and EP(4) receptor activation and platelet function in whole blood.
    Schober LJ; Khandoga AL; Dwivedi S; Penz SM; Maruyama T; Brandl R; Siess W
    J Thromb Thrombolysis; 2011 Aug; 32(2):158-66. PubMed ID: 21424266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mode of action of P2Y(12 ) antagonists as inhibitors of platelet function.
    Iyú D; Glenn JR; White AE; Fox SC; van Giezen H; Nylander S; Heptinstall S
    Thromb Haemost; 2011 Jan; 105(1):96-106. PubMed ID: 20941457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential regulation of airway smooth muscle cell migration by E-prostanoid receptor subtypes.
    Aso H; Ito S; Mori A; Suganuma N; Morioka M; Takahara N; Kondo M; Hasegawa Y
    Am J Respir Cell Mol Biol; 2013 Mar; 48(3):322-9. PubMed ID: 23221043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reciprocal regulation of human platelet function by endogenous prostanoids and through multiple prostanoid receptors.
    Hubertus K; Mischnik M; Timmer J; Herterich S; Mark R; Moulard M; Walter U; Geiger J
    Eur J Pharmacol; 2014 Oct; 740():15-27. PubMed ID: 25003953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo intra-luteal implants of prostaglandin (PG) E1 or E2 (PGE1, PGE2) prevent luteolysis in cows. II: mRNA for PGF2α, EP1, EP2, EP3 (A-D), EP3A, EP3B, EP3C, EP3D, and EP4 prostanoid receptors in luteal tissue.
    Weems YS; Bridges PJ; Jeoung M; Arreguin-Arevalo JA; Nett TM; Vann RC; Ford SP; Lewis AW; Neuendorff DA; Welsh TH; Randel RD; Weems CW
    Prostaglandins Other Lipid Mediat; 2012 Jan; 97(1-2):60-5. PubMed ID: 22120546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prostaglandin E2 receptor EP4 is expressed by human platelets and potently inhibits platelet aggregation and thrombus formation.
    Philipose S; Konya V; Sreckovic I; Marsche G; Lippe IT; Peskar BA; Heinemann A; Schuligoi R
    Arterioscler Thromb Vasc Biol; 2010 Dec; 30(12):2416-23. PubMed ID: 21071691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interaction of eosinophils with endothelial cells is modulated by prostaglandin EP4 receptors.
    Konya V; Philipose S; Bálint Z; Olschewski A; Marsche G; Sturm EM; Schicho R; Peskar BA; Schuligoi R; Heinemann A
    Eur J Immunol; 2011 Aug; 41(8):2379-89. PubMed ID: 21681739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective activation of the prostaglandin E2 receptor subtype EP2 or EP4 leads to inhibition of platelet aggregation.
    Kuriyama S; Kashiwagi H; Yuhki K; Kojima F; Yamada T; Fujino T; Hara A; Takayama K; Maruyama T; Yoshida A; Narumiya S; Ushikubi F
    Thromb Haemost; 2010 Oct; 104(4):796-803. PubMed ID: 20664890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostaglandin E2 levels and platelet function are different in cord blood compared to adults.
    Schlagenhauf A; Haidl H; Leschnik B; Leis HJ; Heinemann A; Muntean W
    Thromb Haemost; 2015 Jan; 113(1):97-106. PubMed ID: 25118631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects on platelet function of an EP3 receptor antagonist used alone and in combination with a P2Y12 antagonist both in-vitro and ex-vivo in human volunteers.
    Fox SC; May JA; Johnson A; Hermann D; Strieter D; Hartman D; Heptinstall S
    Platelets; 2013; 24(5):392-400. PubMed ID: 22866894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A noble function of BAY 11-7082: Inhibition of platelet aggregation mediated by an elevated cAMP-induced VASP, and decreased ERK2/JNK1 phosphorylations.
    Lee HS; Kim SD; Lee WM; Endale M; Kamruzzaman SM; Oh WJ; Cho JY; Kim SK; Cho HJ; Park HJ; Rhee MH
    Eur J Pharmacol; 2010 Feb; 627(1-3):85-91. PubMed ID: 19913011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of P2Y(14) protein in platelets and investigation of the role of P2Y(14) in platelet function in comparison with the EP(3) receptor.
    Dovlatova N; Wijeyeratne YD; Fox SC; Manolopoulos P; Johnson AJ; White AE; Latif ML; Ralevic V; Heptinstall S
    Thromb Haemost; 2008 Aug; 100(2):261-70. PubMed ID: 18690346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostaglandin E2 promotes liver cancer cell growth by the upregulation of FUSE-binding protein 1 expression.
    Ma J; Chen M; Xia SK; Shu W; Guo Y; Wang YH; Xu Y; Bai XM; Zhang L; Zhang H; Zhang M; Wang YP; Leng J
    Int J Oncol; 2013 Mar; 42(3):1093-104. PubMed ID: 23338277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Opposing effects of prostaglandin E
    Carboneau BA; Allan JA; Townsend SE; Kimple ME; Breyer RM; Gannon M
    Mol Metab; 2017 Jun; 6(6):548-559. PubMed ID: 28580285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.